Brief: KALA BIO Reports Second Quarter 2023 Financial Results

KALA BIO

04/08/2023 13:08

Aug 4 (Reuters) - Kala Bio Inc  KALA.O :
    * KALA BIO REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND
PROVIDES CORPORATE UPDATE
    * Q2 LOSS PER SHARE $4.36
    * ACTIVELY ENROLLING PATIENTS IN CHASE PHASE 2B CLINICAL
TRIAL OF
KPI-012 FOR TREATMENT OF PCED; TOPLINE DATA TARGETED FOR 2Q 2024
    * AS OF JUNE 30, 2023, $59.2 MILLION IN CASH, CASH
EQUIVALENTS AND
SHORT-TERM INVESTMENTS
    * CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WITH
$15.0
MILLION CIRM AWARD EXPECTED TO FUND OPERATIONS INTO 2Q 2025
    * QTRLY NET LOSS PER SHARE $4.36
    * Q2 EARNINGS PER SHARE VIEW $-3.19 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3fHFzN 
Further company coverage:  KALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))